The hypothesis is that C15 should be an essential amino acid. I'm not sure where you looked but I suggest Google Scholar "health benefits Pentadecanoic acid" There are tons of peer-reviewed studies on this fat.
Mounting evidence shows that Pentadecanoic acid, or C15:0, an essential fatty acid, is as beneficial as anti-aging drug rapamycin, including sharing anti-inflammatory, anticancer, antifibrotic and antimicrobial activities, according to research published in Nutrients.
www.nutraingredients-usa.com
This work was funded in part by the Office of Naval Research (Agreement No. N00014-2109-0002); NJS data analysis efforts are supported in part by NIH grants U19 AG023122, UH3 AG064706, U19 AG065169."
Conflicts of Interest
The authors declare no conflict of interest.
I found the peer reviewed study source of the link you shared above with exactly the same Office of Naval Research Agreement and it stated a conflict of interest:
Pentadecanoic acid (C15:0) is an essential odd-chain saturated fatty acid with broad activities relevant to protecting cardiometabolic, immune, and liver health. C15:0 activates AMPK and inhibits mTOR, both of which are core components of the human longevity pathway. To assess the potential for...
www.mdpi.com
Funding
This work was funded in part by the Office of Naval Research (Agreement No. N00014-2109-0002); NJS data analysis efforts are supported in part by NIH grants U19 AG023122, UH3 AG064706, U19 AG065169.
Author Contributions
Conceptualization,
S.V.-W. (
Stephanie K. Venn-Watson) and N.J.S methodology, S.V.-W. and N.J.S.; software, S.V.-W.; validation, S.V.-W. and N.J.S.; formal analysis, S.V.-W. and N.J.S.; investigation, S.V.-W. and N.J.S.; resources, S.V.-W. and N.J.S.; data curation, S.V.-W.; writing—original draft preparation, S.V.-W. and N.J.S.; writing—review and editing, S.V.-W. and N.J.S.; visualization, S.V.-W.; supervision, S.V.-W.; project administration, S.V.-W.; funding acquisition, S.V.-W. All authors have read and agreed to the published version of the manuscript.
Conflicts of Interest
S.V.-W. (Stephanie K. Venn-Watson) is a co-founder of and employed by Epitracker, Inc and Seraphina Therapeutics, Inc, which hold exclusive licensing rights from the U.S. Navy
to commercialize odd-chain saturated fatty acids as human and animal health products. NJS is a co-founder of and consultant to Seraphina Therapeutics, Inc.
Here's another study by Stephanie K. Venn-Watson
A growing body of evidence supports that pentadecanoic acid (C15:0), an odd-chain saturated fat found in butter, is an essential fatty acid that is necessary in the diet to support long-term metabolic and heart health. Here, dose dependent and ...
www.ncbi.nlm.nih.gov
Funding Statement
This work was funded by the Office of Naval Research (SBIR Award No. N6833518C0746,
www.onr.navy.mil) received by SV and Epitracker, Inc. (
www.epitracker.com).
SV (Stephanie K. Venn-Watson) receives salary from Epitracker, Inc. and Seraphina Therapeutics, Inc. The funders, other than the named authors, had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.
Another article by Stephanie K. Venn-Watson
Groundbreaking research by veterinarians helping dolphins uncovers the anti-aging benefits of Fatty15. Explore how this unique fatty acid promotes longevity and health.
connect.gdx.net
Apparently, these articles are based on studies made by people who founded a company who plans to sell C15. Even if they're 100% legit, the circumstances these studies are made greatly increase the chance of biased analysis/reports.
The claimed effects of C15 like autophagy, reduced inflammation, activation of AMPK, inhibition of mTOR, etc.
Is exactly the same thing that fasting achieves.
But I'd rather go with fasting because it's time tested and proven.